Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
Registered Address
gsk medicines research centre, gunnels wood road, stevenage, SG1 2NY
glaxosmithkline intellectual property development limitedEstimated Valuation
£9.5b
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED at £9.5b based on a Turnover of £2.4b and 3.96x industry multiple (adjusted for size and gross margin).
glaxosmithkline intellectual property development limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED at £0 based on an EBITDA of £-679.6m and a 16.55x industry multiple (adjusted for size and gross margin).
glaxosmithkline intellectual property development limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED at £0 based on Net Assets of £-17.8b and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Intellectual Property Development LimitedOverview
Glaxosmithkline Intellectual Property Development Limited is a live company located in stevenage, SG1 2NY with a Companies House number of 08283222. It operates in the activities of other holding companies n.e.c. sector, SIC Code 64209. Founded in November 2012, it's largest shareholder is
glaxosmithkline intellectual property management ltd
with a 100% stake. Glaxosmithkline Intellectual Property Development Limited is a established,
mega sized company, Pomanda has estimated its turnover at
£2.4b with
rapid
growth in recent years.
Glaxosmithkline Intellectual Property Development Limited Health Check
Pomanda's financial health check has awarded Glaxosmithkline Intellectual Property Development Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
5 Strong
1 Regular
3 Weak
Size
annual sales of £2.4b, make it larger than the average company (£18.9m)
£2.4b - Glaxosmithkline Intellectual Property Development Limited
£18.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 48%, show it is growing at a faster rate (10.5%)
48% - Glaxosmithkline Intellectual Property Development Limited
10.5% - Industry AVG
Production
with a gross margin of 79.9%, this company has a lower cost of product (36.3%)
79.9% - Glaxosmithkline Intellectual Property Development Limited
36.3% - Industry AVG
Profitability
an operating margin of -29.9% make it less profitable than the average company (4.5%)
-29.9% - Glaxosmithkline Intellectual Property Development Limited
4.5% - Industry AVG
Employees
with 12555 employees, this is above the industry average (104)
12555 - Glaxosmithkline Intellectual Property Development Limited
104 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Development Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £190.9k, this is equally as efficient (£191k)
£190.9k - Glaxosmithkline Intellectual Property Development Limited
£191k - Industry AVG
Debtor Days
it gets paid by customers after 2 days, this is earlier than average (45 days)
2 days - Glaxosmithkline Intellectual Property Development Limited
45 days - Industry AVG
Creditor Days
its suppliers are paid after 6 days, this is quicker than average (44 days)
6 days - Glaxosmithkline Intellectual Property Development Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Development Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Development Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 836.5%, this is a higher level of debt than the average (69.6%)
836.5% - Glaxosmithkline Intellectual Property Development Limited
69.6% - Industry AVG
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED financials
EXPORT
Glaxosmithkline Intellectual Property Development Limited's latest turnover from December 2023 is £2.4 billion and the company has net assets of -£17.8 billion. According to their latest financial statements, we estimate that Glaxosmithkline Intellectual Property Development Limited has 12,555 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Turnover
2,397,360,000
1,628,525,000
1,590,336,000
734,224,000
432,766,000
911,754,000
91,845,000
56,677,000
78,431,000
Other Income Or Grants
Cost Of Sales
481,537,000
417,251,000
427,174,000
441,191,000
450,438,000
532,729,000
411,057,000
425,013,000
571,592,000
462,701,000
83,514,000
Gross Profit
1,915,823,000
1,211,274,000
1,163,162,000
293,033,000
-17,672,000
379,025,000
-319,212,000
-425,013,000
-571,592,000
-406,024,000
-5,083,000
Admin Expenses
2,631,799,000
2,631,376,000
2,619,092,000
2,776,774,000
2,375,872,000
2,072,058,000
2,273,726,000
1,914,552,000
1,660,604,000
1,730,694,000
1,850,593,000
Operating Profit
-715,976,000
-1,420,102,000
-1,455,930,000
-2,483,741,000
-2,393,544,000
-1,693,033,000
-2,592,938,000
-2,339,565,000
-2,232,196,000
-2,136,718,000
-1,855,676,000
Interest Payable
901,379,000
266,271,000
45,637,000
61,556,000
114,460,000
86,774,000
44,836,000
39,586,000
30,069,000
15,758,000
3,116,000
Interest Receivable
1,000
3,000
3,000
239,000
126,000
Pre-Tax Profit
-1,617,354,000
-1,686,370,000
-1,501,564,000
-2,545,058,000
-2,507,878,000
-1,779,807,000
-2,637,774,000
-2,379,151,000
-2,262,265,000
-2,152,476,000
-1,858,792,000
Tax
323,739,000
330,468,000
508,290,000
557,427,000
449,542,000
323,786,000
496,152,000
481,338,000
408,661,000
459,904,000
425,938,000
Profit After Tax
-1,293,615,000
-1,355,902,000
-993,274,000
-1,987,631,000
-2,058,336,000
-1,456,021,000
-2,141,622,000
-1,897,813,000
-1,853,604,000
-1,692,572,000
-1,432,854,000
Dividends Paid
Retained Profit
-1,293,615,000
-1,355,902,000
-993,274,000
-1,987,631,000
-2,058,336,000
-1,456,021,000
-2,141,622,000
-1,897,813,000
-1,853,604,000
-1,692,572,000
-1,432,854,000
Employee Costs
Number Of Employees
12,555
9,114
9,884
4,849
2,798
5,860
591
1
1
361
517
EBITDA*
-679,582,000
-1,375,544,000
-1,415,379,000
-2,371,712,000
-2,334,648,000
-1,636,586,000
-2,563,304,000
-2,316,988,000
-2,230,708,000
-2,095,275,000
-1,806,566,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Tangible Assets
473,252,000
380,072,000
Intangible Assets
307,451,000
420,630,000
508,702,000
435,670,000
478,428,000
395,381,000
437,545,000
449,443,000
355,263,000
270,747,000
239,492,000
Investments & Other
1,516,060,000
1,302,675,000
1,150,893,000
828,613,000
26,969,000
26,969,000
158,980,000
83,554,000
86,995,000
Debtors (Due After 1 year)
Total Fixed Assets
1,823,511,000
1,723,305,000
1,659,595,000
1,264,283,000
951,680,000
775,453,000
596,525,000
532,997,000
442,258,000
270,747,000
239,492,000
Stock & work in progress
Trade Debtors
17,645,000
13,087,000
18,755,000
12,535,000
3,092,000
121,000
2,029,000
Group Debtors
274,209,000
56,133,000
61,493,000
587,206,000
396,360,000
579,443,000
386,515,000
34,715,000
351,424,000
312,263,000
1,502,000
Misc Debtors
294,987,000
382,649,000
391,518,000
339,190,000
6,540,000
4,226,000
584,813,000
521,944,000
445,570,000
527,490,000
446,035,000
Cash
42,000
38,000
35,000
misc current assets
3,226,000
292,570,000
291,775,000
5,056,000
13,070,000
4,806,000
total current assets
586,841,000
451,869,000
471,766,000
942,157,000
698,562,000
875,486,000
976,384,000
569,767,000
801,956,000
841,782,000
447,537,000
total assets
2,410,352,000
2,175,174,000
2,131,361,000
2,206,440,000
1,650,242,000
1,650,939,000
1,572,909,000
1,102,764,000
1,244,214,000
1,112,529,000
687,029,000
Bank overdraft
13,454,000
Bank loan
Trade Creditors
8,189,000
25,977,000
6,911,000
14,086,000
15,034,000
7,371,000
12,297,000
34,181,000
21,212,000
40,716,000
Group/Directors Accounts
20,034,283,000
18,512,591,000
17,062,352,000
16,075,467,000
10,063,949,000
7,477,114,000
5,746,151,000
3,763,819,000
1,660,834,000
other short term finances
2,000
22,000
512,000
469,000
769,000
hp & lease commitments
other current liabilities
114,763,000
88,798,000
151,196,000
212,373,000
13,741,210,000
11,692,921,000
89,660,000
56,013,000
43,582,000
45,261,000
21,533,000
total current liabilities
20,157,235,000
18,627,368,000
17,220,481,000
16,302,438,000
13,756,713,000
11,700,292,000
10,166,675,000
7,567,308,000
5,810,945,000
3,822,534,000
1,723,083,000
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
4,062,000
5,136,000
provisions
12,308,000
12,156,000
28,104,000
25,668,000
12,400,000
3,122,000
total long term liabilities
4,062,000
5,136,000
12,308,000
12,156,000
14,052,000
12,834,000
12,400,000
3,122,000
total liabilities
20,161,297,000
18,632,504,000
17,232,789,000
16,314,594,000
13,770,765,000
11,713,126,000
10,179,075,000
7,567,308,000
5,810,945,000
3,825,656,000
1,723,083,000
net assets
-17,750,945,000
-16,457,330,000
-15,101,428,000
-14,108,154,000
-12,120,523,000
-10,062,187,000
-8,606,166,000
-6,464,544,000
-4,566,731,000
-2,713,127,000
-1,036,054,000
total shareholders funds
-17,750,945,000
-16,457,330,000
-15,101,428,000
-14,108,154,000
-12,120,523,000
-10,062,187,000
-8,606,166,000
-6,464,544,000
-4,566,731,000
-2,713,127,000
-1,036,054,000
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Operating Activities
Operating Profit
-715,976,000
-1,420,102,000
-1,455,930,000
-2,483,741,000
-2,393,544,000
-1,693,033,000
-2,592,938,000
-2,339,565,000
-2,232,196,000
-2,136,718,000
-1,855,676,000
Depreciation
Amortisation
36,394,000
44,558,000
40,551,000
112,029,000
58,896,000
56,447,000
29,634,000
22,577,000
1,488,000
41,443,000
49,110,000
Tax
323,739,000
330,468,000
508,290,000
557,427,000
449,542,000
323,786,000
496,152,000
481,338,000
408,661,000
459,904,000
425,938,000
Stock
Debtors
134,972,000
-19,897,000
-467,165,000
532,939,000
-177,677,000
-387,659,000
414,669,000
-240,456,000
-44,667,000
394,245,000
447,537,000
Creditors
-17,788,000
19,066,000
-7,175,000
-948,000
7,663,000
-4,926,000
-21,884,000
12,969,000
21,212,000
-40,716,000
40,716,000
Accruals and Deferred Income
25,965,000
-62,398,000
-61,177,000
-13,528,837,000
2,048,289,000
11,603,261,000
33,647,000
12,431,000
-1,679,000
23,728,000
21,533,000
Deferred Taxes & Provisions
-12,308,000
152,000
-15,948,000
2,436,000
13,268,000
12,400,000
-3,122,000
3,122,000
Cash flow from operations
-482,638,000
-1,080,819,000
-508,124,000
-15,892,957,000
350,959,000
10,686,462,000
-2,457,658,000
-1,569,794,000
-1,760,969,000
-2,043,482,000
-1,765,916,000
Investing Activities
capital expenditure
76,785,000
43,514,000
-113,583,000
403,981,000
-235,123,000
-394,355,000
-17,736,000
-116,757,000
-86,004,000
-72,698,000
-288,602,000
Change in Investments
213,385,000
151,782,000
322,280,000
801,644,000
-132,011,000
75,426,000
-3,441,000
86,995,000
cash flow from investments
-136,600,000
-108,268,000
-435,863,000
-397,663,000
-235,123,000
-262,344,000
-93,162,000
-113,316,000
-172,999,000
-72,698,000
-288,602,000
Financing Activities
Bank loans
Group/Directors Accounts
1,521,692,000
1,450,239,000
986,885,000
16,075,467,000
-10,063,949,000
2,586,835,000
1,730,963,000
1,982,332,000
2,102,985,000
1,660,834,000
Other Short Term Loans
-2,000
-20,000
-490,000
43,000
469,000
-769,000
769,000
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-1,074,000
5,136,000
share issue
15,499,000
396,800,000
interest
-901,378,000
-266,268,000
-45,634,000
-61,317,000
-114,334,000
-86,774,000
-44,836,000
-39,586,000
-30,069,000
-15,758,000
-3,116,000
cash flow from financing
619,238,000
1,189,087,000
940,761,000
16,014,193,000
-113,865,000
-10,151,492,000
2,542,768,000
1,691,377,000
1,952,263,000
2,102,726,000
2,054,518,000
cash and cash equivalents
cash
-42,000
42,000
-38,000
3,000
35,000
overdraft
-13,454,000
13,454,000
change in cash
-42,000
42,000
-38,000
3,000
13,489,000
-13,454,000
glaxosmithkline intellectual property development limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for glaxosmithkline intellectual property development limited. Get real-time insights into glaxosmithkline intellectual property development limited's credit score, group structure and payment trends.
Glaxosmithkline Intellectual Property Development Limited Competitor Analysis
Perform a competitor analysis for glaxosmithkline intellectual property development limited by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other mega companies, companies in SG1 area or any other competitors across 12 key performance metrics.
glaxosmithkline intellectual property development limited Ownership
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED group structure
Glaxosmithkline Intellectual Property Development Limited has no subsidiary companies.
glaxosmithkline intellectual property development limited directors
Glaxosmithkline Intellectual Property Development Limited currently has 6 directors.
The longest serving directors include
Mr Adam Walker (Mar 2013) and
Mr James Wheatcroft (Jul 2019).
glaxosmithkline intellectual property development limited company details
company number
08283222
Type
Private limited with Share Capital
industry
64209 - Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
gsk medicines research centre, gunnels wood road, stevenage, SG1 2NY
Bank
-
Legal Advisor
-
glaxosmithkline intellectual property development limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline intellectual property development limited.
glaxosmithkline intellectual property development limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED. This can take several minutes, an email will notify you when this has completed.
glaxosmithkline intellectual property development limitedCompanies House Filings - See Documents
